Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01004081 · ClinicalTrials.gov registry record · Phase 2
Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding
A Phase 2 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT01004081 is a Phase 2 study that has completed, run by Biogen. The registered enrollment target is 54 participants.
The verdict
NCT01004081, a Phase 2 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy, safety and tolerability of 2 dosing regimens of BIIB021 in combination with exemestane in women whose HR+ breast cancer had progressed following treatment with a nonsteroidal aromatase inhibitor (AI).
Interventions
- DRUG BIIB021
- DRUG exemestane (Aromasin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01004081
The ClinicalTrials.gov registry entry for NCT01004081 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BIIB021 is the first listed.
NCT01004081 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01004081 about?
NCT01004081 is a clinical study titled "Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding". The purpose of this study is to assess the efficacy, safety and tolerability of 2 dosing regimens of BIIB021 in combination with exemestane in women whose HR+ breast cancer had progressed following treatment with a nonsteroidal aromatase inhibitor (AI).
What is the current status of trial NCT01004081?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2009-11. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01004081?
The interventions under investigation include: BIIB021 (DRUG), exemestane (Aromasin) (DRUG).
Who is sponsoring clinical trial NCT01004081?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.